Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1478000 | 0.82 | LOX (0.35) | LOX | |
| SCHEMBL24216636 | 0.81 | HSD17B10 (0.32) | — | |
| SCHEMBL30408012 | 0.81 | HSD17B10 (0.32) | — | |
| SCHEMBL16396634 | 0.81 | RECQL (0.31) | — | |
| SCHEMBL1476913 | 0.79 | GRM5 (0.40) | GRM5 | |
| SCHEMBL29434830 | 0.79 | GRM5 (0.40) | GRM5 | |
| SCHEMBL854029 | 0.79 | GRM5 (0.57) | GRM5 | |
| SCHEMBL8490064 | 0.78 | VCAM1 (0.41) | TSHR | |
| SCHEMBL29980428 | 0.78 | VCAM1 (0.41) | TSHR | |
| SCHEMBL24132797 | 0.77 | LOX (0.30) | LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122187-A1 | ANTI-BIOFILM COMPOUNDS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-12215104-B2 | Anti-biofilm compounds | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20210188838-A1 | ANTI-BIOFILM COMPOUNDS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| WO-2020023318-A1 | ANTI-BIOFILM COMPOUNDS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| EP-2822956-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20130261077-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261077-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261077-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2013134415-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-12 | — | — | WO | disclosed |
| EP-1425010-B8 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | JANSSEN PHARMACEUTICALS INC (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-09-22 | — | — | US | disclosed |
| US-6855722-B2 | Substituted indoles and their use as integrin antagonists | DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| EP-1425010-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20030199451-A1 | Combination therapy using a dual PPAR-a/PPAR-y activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders | HIGH POINT PHARMACEUTICALS, LLC | 2003-10-23 | — | — | US | disclosed |
| US-6569901-B2 | (E)-(S)-2-Ethoxy-3-(4-(5-phenyl-pent-2-en-4-ynyloxy)-phenyl)-propionic acid, ethyl ester for example; treating conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR); diabetes, obesity | NOVO NORDISK A/S (DK) | 2003-05-27 | — | — | US | disclosed |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| EP-1254102-A1 | ALKYNYLSUBSTITUTED PROPIONIC ACID DERIVATIVES AND THEIR USE AGAINST DIABETES AND OBESITY | Novo Nordisk A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| WO-2002060438-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| US-20010041709-A1 | New compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2001-11-15 | — | — | US | disclosed |
| WO-2001055086-A1 | ALKYNYLSUBSTITUTED PROPIONIC ACID DERIVATIVES AND THEIR USE AGAINST DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041709-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | TSHR 578/4885GRM5 615/4885LOX 1656/4885 |
| US-20250122187-A1 | ANTI-BIOFILM COMPOUNDS | FGB, SELP, SPPL2B | TSHR 1829/4885GRM5 3290/4885LOX 3011/4885 |
| US-20130261077-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | MPI, MANBA, MAN2A1 | TSHR 4513/4885GRM5 2033/4885LOX 744/4885 |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGA5, ITGB5 | TSHR 130/4885GRM5 600/4885LOX 2008/4885 |
| US-12215104-B2 | Anti-biofilm compounds | FGB, SELP, SPPL2B | TSHR 1829/4885GRM5 3290/4885LOX 3011/4885 |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGAL, ITGA5 | TSHR 156/4885GRM5 554/4885LOX 1316/4885 |
| US-20030199451-A1 | Combination therapy using a dual PPAR-a/PPAR-y activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders | GLP1R, PPARG, PPARA | TSHR 164/4885GRM5 279/4885LOX 3796/4885 |
| US-20210188838-A1 | ANTI-BIOFILM COMPOUNDS | FGB, SELP, SPPL2B | TSHR 1829/4885GRM5 3290/4885LOX 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.